Clearing the fog: Is HCQ effective in reducing COVID 19 progression: A randomized controlled trial
Objective: To analyze the efficacy of Hydroxychloroquine (HCQ) plus standard of care (SOC) compared with SOC alone in reducing disease progression in Mild COVID 19 Design: A single centre, open label randomized controlled trial Place and Duration: Pulmonology department, Pak emirates Military Hospital (PEMH) from 10 April 2020 to 31 May 2020. Methodology: Five hundred patients of both genders having age between 18 50 years who were PCR positive and had Mild COVID 19 were selected. Patients assigned to standard dose of HCQ (400mg 12 hourly day 1 then 200mg 12 hrly for next 4 days) plus SOC were 349 while 151 patients received SOC comprising of Vit C, Vit D, and Zinc only (control group) Primary outcome was progression of disease while secondary outcome was PCR negativity on day 7 and 14. The results were analyzed on SPSS version 23. P value <0.05 was considered significant. Results: Median age of intervention group (34 11.778 years) and control group (34 9.813 years) Disease progressed in 16 patients, 11 (3.15% were in intervention group as compared to 5 (3.35% in control group, (p value 0.865) PCR negativity in intervention and control groups were (day 7, 182 (52.1% vs. 54 (35.7% (p value 0.001) (day 14, 244 (69.9% vs. 110 (72.8% (p value 0.508) Consecutive PCR negativity at day 7 and 14 was observed in 240 (68.8% in intervention group compared to 108 (71.5% in control group. (p value 0.231) Conclusion: Addition of HCQ to standard of care treatment in Mild COVID 19 neither prevents disease progression nor is it significantly associated with successive PCR negativity on day 7 and 14.
medRxiv